Compass Therapeutics to Participate in Upcoming December Investor Events




Compass Therapeutics to Participate in Upcoming December Investor Events

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of December.

Details are as follows:

Piper Sandler 37^th Annual Healthcare Conference
Location: New York, NY
Date: Tuesday, December 2, 2025
Time: 8:00 AM ET
Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1744426&tp_key=c56d01f519

8^th Annual Evercore Healthcare Conference
Location: Coral Gables, FL
Date: Thursday, December 4, 2025
Time: 10:00 AM ET
Webcast Link: https://wsw.com/webcast/evercore52/cmpx/2381104

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com 

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com 
617-500-8099

Compass Therapeutics to Participate in Upcoming December Investor Events




Compass Therapeutics to Participate in Upcoming December Investor Events

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of December.

Details are as follows:

Piper Sandler 37^th Annual Healthcare Conference
Location: New York, NY
Date: Tuesday, December 2, 2025
Time: 8:00 AM ET
Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1744426&tp_key=c56d01f519

8^th Annual Evercore Healthcare Conference
Location: Coral Gables, FL
Date: Thursday, December 4, 2025
Time: 10:00 AM ET
Webcast Link: https://wsw.com/webcast/evercore52/cmpx/2381104

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These pathways include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com 

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com 
617-500-8099

CytomX Therapeutics to Present at Upcoming December Investor Conferences




CytomX Therapeutics to Present at Upcoming December Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December.

8^th Annual Evercore Healthcare Conference
Date: Tuesday, December 2, 2025
Fireside Chat: 1:45 p.m. ET
Location: Coral Gables, FL

Piper Sandler 37^th Annual Healthcare Conference
Date: Thursday, December 4, 2025
Fireside Chat: 1:00 p.m. ET
Location: New York, NY

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics, Inc.

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY^® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com

Adalyon Appoints Ulrik Zeuthen as CEO to Drive Next Phase of Growth in AI-driven Speech-based Biomarkers and Behavioural Analytics for Optimising Clinical Trials




Adalyon Appoints Ulrik Zeuthen as CEO to Drive Next Phase of Growth in AI-driven Speech-based Biomarkers and Behavioural Analytics for Optimising Clinical Trials

ESPOO, Finland, Nov. 25, 2025 (GLOBE NEWSWIRE) — Adalyon, a pioneering tech-bio company using its AI-powered speech biomarker platform to transform clinical drug development, today announced the appointment of Ulrik Zeuthen, as Chief Executive Officer (CEO). Ulrik is an experienced leader in driving digital transformation in the pharmaceutical industry through data integration and artificial intelligence (AI). Adalyon’s proprietary speech-based digital biomarkers provide actionable insights into cognitive and behavioural patient outcomes, helping optimise clinical research.

Ulrik brings extensive experience from the pharmaceutical and data science sectors, having previously held Director level positions at Novo Nordisk, working in Denmark and Japan, and as a data strategist at Deloitte. He has been responsible for the establishment and execution of partnerships between Novo Nordisk and primary technical partners, to drive the scaled and accelerated AI use case delivery across the company. He holds a Masters of Science (MSc) in Economics from the University of Copenhagen, Denmark.

“I’m excited to join Adalyon, to leverage the deep expertise of the team and the company’s strong heritage in behavioural science and technology R&D for real impact. Adalyon’s proprietary methodology utilising modern AI/ML capabilities in highly regulated environments stands out as market shaping. We’re pioneering quantified behavioural analytics to modernize clinical research,” said Ulrik Zeuthen, CEO of Adalyon. “I’m looking forward to showcasing the value of our AI-powered Behavioural Intelligence Platform in delivering real-time behavioural and emotional insights for clinical trials and healthcare applications. Specifically, our adaptable ‘patient-centric’ approach is designed as a plug-and-play technology, driving better patient stratification and retention in trials, and with the potential to identify benefits in additional indications, enabling product label extensions and early detection of treatment effects. Our technology has the potential to add tremendous value to pharmaceutical R&D programmes by improving clinical trial outcomes and ultimately delivering more effective drugs and patient outcomes.”

Founder of Adalyon, Katarina Cantell, will transition to the role of Chief Scientific Officer (CSO). Dr Cantell holds a PhD in information systems and has conducted doctoral research at Stanford University at the intersection of behavioural sciences and technology. She brings over 20 years of experience in digital health and strategic leadership, including executive roles at Aava Medical and TietoEvry with her earlier career stemming from Polar Electro, wearables and the evolution of HRV into a digital biomarker.

Dr Katarina Cantell, CSO and Founder of Adalyon commented, “Ulrik’s expertise in applying AI/ML & analytics in life sciences together with his entrepreneur background and growth mindset makes him ideal to lead Adalyon into its next chapter as we seek partnerships with pharmaceutical companies to support them in optimising clinical trials and enabling greater insights into a patient’s drug response profiles. Adalyon’s proprietary speech-based digital biomarker technology is designed to capture the true voice of the patient, not just what their blood tests may say. We could say that speech is the new blood, and we’re using it to strive for a digital revolution in clinical drug development.”

The current way of measuring behavioural phenomena and drug response signals in clinical trials relies heavily on questionnaires and invasive samples, which are often episodic, rigid, and burdensome for participants. This contributes to dropout rates reaching 40-50% and in many cases also incomplete and biased data. Adalyon’s technology aims to address this burden and data gap by providing a non-invasive, high-frequency signal that improves sensitivity, reduces noise, and accelerates go/no-go decisions. By seamlessly integrating into the current process, it enables sponsors to recruit and retain the right participants and engage and monitor them more effectively to support earlier detection of treatment responses and raise primary outcomes.

About Adalyon

Adalyon is a pioneering tech-bio company transforming natural human speech into next-generation digital biomarkers that optimise clinical trial design and execution. Founded on a deep behavioural science foundation, the company’s proprietary AI-based technology converts speech and text into quantitative biomarkers that capture subtle cognitive and emotional changes in trial participants, helping pharmaceutical sponsors and CROs improve patient selection, engagement, and retention in clinical trials.

Adalyon’s solution is designed as a ‘plug and play’ technology that seamlessly integrates into existing trial infrastructures to complement, rather than replace, traditional data collection. This approach helps reduce participant burden and dropout rates, deliver measurable quality-of-life insights, and enable more efficient, outcome-driven trials.

Using advanced natural language processing (NLP), large language models (LLMs), and its proprietary Ayda Insights behavioural analytics AI, Adalyon extracts real-time, unbiased intelligence from natural speech.

Adalyon is looking to collaborate with pharmaceutical partners and clinical research organisations to enable more effective patient stratification and retention, earlier detection of treatment effects, and deliver more data-driven, patient-centric outcomes.

With offices in Espoo, Finland, and Copenhagen, Denmark, Adalyon is led by a multidisciplinary, international team of experts in behavioural science, AI engineering, and computational linguistics, advancing the new era of speech biomarkers in life sciences.

Visit www.adalyon.com and follow Adalyon on LinkedIn.

Media contacts

Adalyon
Ulrik Zeuthen – CEO
ulrik.zeuthen@adalyon.com

Scius Communications 
Katja Stout
+44 778 943 5990
katja@sciuscommunications.com
Daniel Gooch
+44 7747 875479
daniel@sciuscommunications.com

Macomics Announces Updated Data of the ENIGMAC Drug Discovery Platform and The Role of Macrophages in Fibrotic Disease




Macomics Announces Updated Data of the ENIGMAC Drug Discovery Platform and The Role of Macrophages in Fibrotic Disease

EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, Nov. 25, 2025 (GLOBE NEWSWIRE) — Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.

Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models combined with proprietary gene editing technology.

There is clear evidence of causal human genetics in fibrosis and the interplay between macrophages and fibroblasts in fibrotic diseases of the liver, lung and kidney. The identification and functional validation of potential first-in-class targets in this area has been limited by the lack of proper technology and macrophage expertise.

Having already proven its first-in-class target validation potential in oncology, ENIGMAC is a proprietary technology developed to produce gene editable macrophages. The platform can knock in or knock out genes of interest via CRISPRa or CRISPRi expression in iPSC derived cells, unlocking the opportunity for new target discovery informed by human data.

For fibrotic disease-related drug discovery, Macomics has focused on the interplay between macrophages and fibroblasts on the deposition of the extracellular matrix seen in fibrosis with a unique co-culture system. Our goal has been to promote fibrosis regression through macrophage targeting, exploring potential first in class approaches.

Luca Cassetta, PhD, co-founder and VP Immunology at Macomics, said, “We have completed and validated gene knock down screenings (pooled and array) in iPS-derived cells in disease relevant models and also demonstrated that gene editing is scalable from single to genome wide.”

In its in-house program, Macomics’ therapeutic strategy has utilized the validated in vitro co-culture assay enabling higher throughput arrayed screening for macrophage antibody-dependent cellular phagocytosis (ADCP) fibroblast targets, with validation in human ex vivo precision-cut lung slices (PCLS), as a strategy to identify additional first in class targets.

Simon Dew, CBO of Macomics, said, “We are now using our ENIGMAC platform for new target discovery in fibrotic diseases, as well as other disease areas, both in-house and in drug discovery partnerships.”

About Macomics – www.macomics.com

Macomics Ltd is a macrophage drug discovery company with a world-leading macrophage drug discovery platform, developing first-in-class medicines to deliver transformational impact for patients with macrophage-driven diseases: Macrophages are key to multiple diseases of high unmet medical need, including as key mediators of solid tumour immunosuppression and pathological inflammation in chronic inflammatory disorders.

The company is progressing a diversified portfolio of therapies targeting disease specific macrophages towards the clinic. Its ENIGMAC macrophage drug discovery platform enables identification and validation of novel macrophage therapeutic targets and provides a translationally relevant path to clinic through the development of more physiologically relevant human macrophage models combined with proprietary gene editing technology.

The company was co-founded in 2020 by Prof. Jeffrey Pollard and Dr. Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology. It has R&D and office facilities in Edinburgh and Cambridge, UK. The company’s financing was led by Epidarex Capital, and the company is backed by Scottish Enterprise, LifeLink Ventures and Caribou Property Limited.

Follow us on LinkedIn

For further information please contact:

Macomics

At the Company – Steve Myatt, CEO, Macomics E: myatt@macomics.com

Media enquiries (for Macomics) – Sue Charles, Charles Consultants T: +44 (0)7968 726585 E: sue@charles-consultants.com

Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million




Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million

• Global license provides American Regent, a wholly owned subsidiary of Daiichi Sankyo, with rights to commercialize Synoglide™ in the veterinary market in most countries of the world. Allegro retains rights to human applications for its technology, enabling the company to focus on human clinical development of its osteoarthritis candidate
• Under the terms of the agreement, Allegro has received an upfront payment and is eligible to receive commercialization and sales milestone payments up to $35 million, in addition to royalties on sales
• Product availability is planned for early 2026

Liege, Belgium and Shirley, NY – 25 November 2025 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, and American Regent, a leading pharmaceutical company in the U.S. specializing in injectables for human and animal health, announced today that the two companies have entered into an exclusive licensing deal for Allegro’s Synoglide™, a novel treatment for osteoarthritis in the equine market.

Under the agreement, Allegro will manufacture Synoglide™ in its state-of-the art cleanroom facility. “The partnership with leading animal health player American Regent is a clear validation of the potential of Allegro’s injectable hydrogel to treat osteoarthritis in the equine veterinary market. Horses serve as a strong translational model for humans in joint disease, an exciting prospect as we focus on human clinical development of the technology,” said Lucas Decuypere, Chief Executive Officer at Allegro.

American Regent plans to introduce Synoglide™ for horses at the American Association of Equine Practitioners conference in December 2025 and expects to achieve first sales in the U.S. in early 2026. “We are eager to add this novel treatment for osteoarthritis to our veterinary portfolio as part of our commitment to innovative solutions that improve animal health. Synoglide™ offers a new approach to help veterinarians manage this challenging chronic condition that affects the lives of so many animals,” said Paul Diolosa, Chief Executive Officer at American Regent.

Synoglide™ is an intra-articular injection for horses suffering from osteoarthritis and is based on Allegro’s proprietary nanotechnology platform, INTRICATE. This technology will be launched for use in horses initially, and is being researched for other animals, including canine patients.

American Regent Inc.® (www.americanregent.com), a Daiichi Sankyo Group company, maker of animal health products Adequan® and BetaVet® is an industry-leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers.

Allegro NV (www.allegro.bio) is a private biomedical company developing transformative treatments for degenerative joint diseases based on its proprietary nanotechnology platform, INTRICATE. The company’s lead product candidate in humans, Hydrocelin, is a first-in-class, potentially disease-modifying medical device candidate for the treatment of osteoarthritis. Allegro is preparing to initiate human clinical studies of Hydrocelin in 2026. Synoglide™ is partnered with American Regent, a subsidiary of Daiichi Sankyo, for further development and global commercialization, excluding the Middle-East.

For more information, please contact:

Important information
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes”, “estimates,” “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company’s actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Attachment

• 20251125 Allegro PR licensing deal (approved final)

RAMSAY SANTE : Press release on November 25 2025




RAMSAY SANTE : Press release on November 25 2025

       
        PRESS RELEASE
                Paris, 25^th November 2025

Update on Ramsay Health Care Limited’s review of its strategic options associated with its majority shareholding in Ramsay Générale de Santé

On 27 February 2025, Ramsay Générale de Santé acknowledged the announcement of its Australian reference shareholder Ramsay Health Care Limited regarding the review of its strategic options associated with its majority shareholding in Ramsay Générale de Santé.

Today, Ramsay Générale de Santé takes note of the press release issued by Ramsay Health Care Limited announcing that it has completed this review with the support of Goldman Sachs.

According to this press release, Ramsay Health Care Limited indicates that its Board and Management are committed to executing one of the options considered as part of this strategic review, and that the market will be provided with an update no later than the publication of Ramsay Health Care Limited’s first half results in February 2026.

The press release issued by Ramsay Health Care Limited can be viewed on its website (www.ramsayhealth.com).

About Ramsay Santé

Ramsay Santé is the European leader in private hospitalisation and primary care. With 40,000 employees and 10,000 practitioners, the group welcomes 13 million patients each year in 492 facilities across five countries (France, Sweden, Norway, Denmark and Italy).

As a mission-driven company, Ramsay Santé covers the entire care pathways in medicine, surgery, obstetrics, medical and rehabilitation care, mental health and primary care centres, with constant innovation to improves everyone’s health and ensures equitable access to secure and qualitative care.

Facebook: https://www.facebook.com/RamsaySante 
Instagram: https://www.instagram.com/ramsaysante 
Twitter: https://twitter.com/RamsaySante 
LinkedIn: https://www.linkedin.com/company/ramsaysante 
YouTube: https://www.youtube.com/c/RamsaySante 

Code ISIN and Euronext Paris: FR0000044471 
Website:  www.ramsaysante.fr 

Investor / Analyst Relations        Press Relations

Clément Lafaix        Brigitte Cachon
Tél. +33 1 87 86 21 52        Tél. +33 1 87 86 22 11
clement.lafaix@ramsaysante.fr        brigitte.cachon@ramsaysante.fr

Attachment

• RAMSAY SANTE – Press Release on November 25 2025

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS




Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

• Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker
• Scemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs
• 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trial
• Kisqali NATALEE and MONALEESA data add to evidence of long-term benefits for early and metastatic breast cancer patients

Basel, November 25, 2025 – Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2025 San Antonio Breast Cancer Symposium^® (SABCS). Featured among these latest advances in hematology and oncology are 11 oral presentations, with the Phase III VAYHIT2 trial for ianalumab in immune thrombocytopenia (ITP) accepted as a late-breaker abstract.

“For decades, Novartis has redefined the future of hematology and oncology, and we’re building on that foundation with compelling new data presented at ASH and SABCS,” said Mark Rutstein, M.D., Global Head, Oncology Development, Novartis. “These data underscore how we seek to set new standards for transformative care, with the aim of turning cutting-edge innovation into meaningful impact for patients.”

Key highlights of data accepted by ASH include:

Key highlights of data accepted by SABCS include:

Product Information

For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products.

Novartis in hematology
Our legacy in hematology runs deep, shaped by over 25 years of progress, partnerships and a commitment to keep asking questions, challenging norms and striving for better answers in a uniquely complex field. In the past two decades, we have delivered more than 10 medicines across more than 15 blood cancers and serious blood disorders including leading the era of targeted therapies in cancer and bringing the first CAR-T therapy to patients.

Innovation in hematology has brought significant progress, yet patients and clinicians continue to face persistent challenges. We’re forging the future of hematology, powered by our foundation in scientific discovery to deliver meaningful change for patients with unmet needs.

Novartis in breast cancer 
For over 30 years, Novartis has been at the forefront of driving scientific advancements for individuals affected by breast cancer and enhancing clinical practice in collaboration with the global community. With one of the most comprehensive breast cancer portfolios and pipeline, Novartis leads the industry in discovery of new therapies and combinations in HR+/HER2- breast cancer, the most common form of the disease. 

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #

Pennsylvania Perio & Implants Announces Strengthened Commitment to Evidence-Based Periodontal and Dental Implant Evaluation in Pennsylvania




Pennsylvania Perio & Implants Announces Strengthened Commitment to Evidence-Based Periodontal and Dental Implant Evaluation in Pennsylvania

York, Pennsylvania, Nov. 24, 2025 (GLOBE NEWSWIRE) — Pennsylvania Perio & Implants today announced the reinforcement of its evidence-based framework for periodontal evaluation and dental implant assessment across its York and Hanover locations. Under the clinical direction of periodontist Dr. Dennis Sourvanos, the practice has placed continued emphasis on evidence-based methodologies to provide structured, measurable insights into periodontal conditions and implant suitability.

The organization states that the initiative reflects an ongoing commitment to clarity, diagnostic rigor, and transparent communication to its patients and referring partners. With periodontal and peri-implant disease affecting a substantial portion of adults in Pennsylvania and throughout the country, the practice highlights the importance of detailed clinical assessment that aligns with current literature and professionally recognized standards. According to the practice, this approach supports consistency in evaluation and fosters a stronger understanding among patients and referring providers to improve oral health in the context of Dental Medicine, without offering implied outcomes or promotional assurances.

In discussing the practice’s direction, Dr. Sourvanos noted the significance of using established scientific criteria when examining periodontal conditions.
“Our evaluation model relies on objective clinical indicators and recognized periodontal parameters,” said Dr. Sourvanos. “By integrating research-supported standards into each assessment, we aim to ensure that every diagnostic step reflects measurable findings and maintains alignment with contemporary expectations in the field of periodontics.”

The practice reports that its clinical methodology includes structured charting of periodontal measurements, such as probing depths and attachment levels; radiographic analysis to identify bone support and anatomical considerations; adjunctive diagnostics, and the use of standard indices that assist in determining the status and progression of gum and/or implant disease. Pennsylvania Perio & Implants notes that this emphasis on quantifiable data is foundational in periodontics and critical for ensuring consistency across patient evaluations.

As part of its focus on evidence-based assessment, the practice has detailed its approach to evaluating potential candidates for dental implants. The organization explains that diagnostic imaging, anatomical reviews, and bone density considerations support a systematic process that adheres to research-supported principles rather than subjective interpretation. Pennsylvania Perio & Implants emphasizes that all implant evaluations are driven by the latest standards of evidence-based research and occur exclusively during clinical consultations.

The practice indicates that the reaffirmation of its methodology also includes a continued effort to strengthen communication with general dentists, dental specialists, hospital systems, and referring partners throughout Pennsylvania and the surrounding region. Clear documentation, treatment rationale summaries, and structured diagnostic reports are provided to referring providers to support continuity of care. Pennsylvania Perio & Implants states that collaborative communication ensures that evaluations remain consistent and transparent from initial diagnosis through follow-up.

As periodontal health remains a central focus for many dental professionals across the region, the organization notes that its evidence-based structure allows for more standardized interpretation of gum disease severity. The practice highlights that conditions such as tissue inflammation, periodontal pocketing, and bone loss require detail-driven evaluation to understand progression, classify disease stages, and outline potential treatment considerations. The announcement emphasizes that Pennsylvania Perio & Implants’ goal is to maintain clarity while avoiding speculation or predictive statements that fall outside accepted clinical boundaries.

The company further notes that public awareness regarding periodontal health has grown, with increasing interest in the role of periodontists in evaluating complex or advanced gum concerns. Pennsylvania Perio & Implants states that this announcement is intended to inform the public about the practice’s continued dedication to structured evaluation methods and evidence-aligned review processes. The release does not present promotional claims, comparative statements, or advice related to treatment choices; it remains focused solely on the organizational update.

In addition, the practice reiterates that its website, pennsylvaniaperioandimplants.com, contains general information about periodontal conditions, dental implant considerations, and the role of a periodontist. These resources are intended for educational purposes and are not meant to replace clinical consultation. The site also includes announcements related to the organization’s operations and its locations serving York and Hanover.

Pennsylvania Perio & Implants emphasizes that this communication reflects its ongoing commitment to maintaining structured, research-informed practices within the field of periodontal care. The organization reports that continuous evaluation of academic literature, clinical guidelines, and diagnostic tools remains central to its long-term approach. The announcement is intended as a factual update for the community and referring dental professionals, consistent with newswire standards and without promotional or advisory intent.

For more information, please visit https://pennsylvaniaperioandimplants.com/.

About Pennsylvania Perio & Implants

Pennsylvania Perio & Implants is a periodontal practice located in York and Hanover, Pennsylvania. The organization provides evaluation and treatment related to periodontal conditions as well as assessment for dental implant considerations. The practice follows evidence-based methodologies designed to support consistent diagnosis and research-aligned decision-making within the field of periodontics.

Media Contact
Company Name: Pennsylvania Perio & Implants
Contact Person: Amin Nassiri
Email: amin@dentistnerds.com
Phone: 3105926293
Country: United States
Website: https://pennsylvaniaperioandimplants.com/

CONTACT: Media Contact
Company Name: Pennsylvania Perio & Implants
Contact Person: Amin Nassiri
Email: amin@dentistnerds.com
Phone: 3105926293
Country: United States
Website: https://pennsylvaniaperioandimplants.com/

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC




Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab injection (subcutaneous injection) (code: JS001sc) or toripalimab injection (code: JS001) in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small-cell lung cancer (“NSQ-NSCLC”) (NCT06505837). Junshi Biosciences plans to submit a new drug application (“NDA”) to the regulatory authorities in the near future.

According to data released by GLOBOCAN 2022, in 2022, China saw 1.06 million new lung cancer cases (22.0% of all new cancer cases in China) and 0.73 million lung cancer deaths (28.5% of all cancer-related deaths in China). NSCLC was the predominant subtype, accounting for approximately 85% of all lung cancer cases. Among NSCLC patients, non-squamous NSCLC constituted approximately 65% of cases.

Immunotherapy (I-O), represented by anti-PD-1 monoclonal antibodies, has become a cornerstone treatment for various malignant tumors including lung cancer, breast cancer, liver cancer, esophageal cancer, and nasopharyngeal carcinoma. Now, immunotherapy covers nearly all stages of treatment for cancer patients, encompassing adjuvant/neoadjuvant treatment for early-stage tumors, consolidation treatment after radical chemoradiation for locally advanced tumors, and first-line to last-line treatments for advanced tumors. Currently, most immunotherapy drugs in China are administered intravenously, and this not only requires lengthy infusion times, but also imposes significant inconveniences on patients. There is an urgent clinical need for more convenient administration methods for immunotherapy.

The JS001sc-002-III-NSCLC Study is a multi-center, open-label, randomized Phase 3 clinical study led by the principal investigator Professor Lin WU from Hunan Cancer Hospital. JS001sc-002-III-NSCLC is the first Phase 3 clinical study of a domestic anti-PD-1 monoclonal antibody subcutaneous formulation.

The study aims to compare the exposure, efficacy and safety of JS001sc plus chemotherapy or JS001 plus chemotherapy for the first-line treatment of recurrent or metastatic NSQ-NSCLC. The results have showed that the drug exposure of JS001sc was non-inferior to that of toripalimab injection with comparable efficacy and safety profiles. The study data will be presented at an upcoming international academic conference. Junshi Biosciences plans to communicate with the regulatory authorities and submit JS001sc’s NDA for all approved indications of JS001.

Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, “Since its launch as China’s first domestically developed PD-1 antibody drug, toripalimab has secured approvals for 12 indications, benefiting a significant number of patients. In clinical practice, we observed that patients undergoing immunotherapy, either as monotherapy or combination maintenance therapy, face challenges such as frequent intravenous catheterization and time-consuming infusions. The recent success of the Phase 3 study for JS001sc, achieved through the efforts of both patients and the research team, marks not only a pivotal breakthrough in transitioning I-O therapy from ‘efficacy’ to ‘convenience’, but also exemplifies Junshi Biosciences’ patient-centric ambition. By innovating drug delivery methods, we enhance treatment accessibility: simplifying procedures for patients, reducing their healthcare burden, and alleviating pressure on medical resources. We are committed to advancing the registration of JS001sc and providing more patients with a better treatment experience alongside clinical benefits.”

About JS001sc
JS001sc, developed by Junshi Biosciences, is a subcutaneous injection formulation based on the marketed product, toripalimab injection. JS001sc is the first domestic anti-PD-1 monoclonal antibody subcutaneous formulation to enter Phase 3 clinical study, and will potentially offer more convenient administration to patients. As of today, a multi-center, open-label, randomized Phase 3 clinical study comparing JS001sc plus chemotherapy or toripalimab injection plus chemotherapy for the first-line treatment of recurrent or metastatic NSQ-NSCLC (the JS001sc-002-III-NSCLC Study) has met its primary endpoints.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Five of the company’s products have received approvals in China and international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 40 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI®, and other novel therapies for the prevention and treatment of COVID-19.

With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://www.junshipharma.com.

Junshi Biosciences Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800